NKTR
HealthcareNektar Therapeutics
$44.47
+$1.05 (+2.42%)
Jan 5, 2026
Price History (1Y)
Analysis
Nektar Therapeutics is a healthcare company within the biotechnology industry, with a market capitalization of $904.59 million and 61 employees. The company operates in the sector of Healthcare. The financial health of Nektar Therapeutics indicates significant losses, with a net income of -$120,736,000 and EBITDA of -$135,195,008 over the trailing twelve months. The company's gross margin is 87.3%, but its operating margin is -267.4% and profit margin is -192.9%. In terms of returns, Nektar Therapeutics has a return on equity of -180.2% and a return on assets of -28.0%. Its balance sheet shows $270.21 million in cash and $167.08 million in debt, resulting in a debt to equity ratio of 196.37. The valuation context for Nektar Therapeutics is marked by negative earnings growth, with a forward P/E ratio of -3.75. The company's price to book ratio is 10.27, its price to sales ratio is 14.45, and its EV/EBITDA ratio is -5.77.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $904.59M
- P/E Ratio
- N/A
- 52-Week High
- $66.92
- 52-Week Low
- $6.45
- Avg Volume
- 850.31K
- Beta
- 1.32
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 61